GLP-1 Medications and Migraine: Why Researchers Are Paying Attention
GLP-1 / Migraine / Metabolic Health
GLP-1 Medications and Migraine: Why Researchers Are Paying Attention
Some patients report fewer migraines after starting GLP-1 medications. The research is still early, but several studies are beginning to explore a possible connection between GLP-1 signaling, migraine frequency, triptan use, CGRP, neuroinflammation, intracranial pressure, obesity, and metabolic health.
GLP-1 medications became known for weight loss. But more recently, patients and researchers have started asking a different question: could these medications also affect migraine biology?
The question is not coming from marketing. It is coming from observation. Some patients who start medications such as semaglutide, liraglutide, or tirzepatide report that their migraines become less frequent. Not everyone notices this, and GLP-1 medications are not approved migraine treatments. Some patients may even experience headache as a side effect.
Still, the patient stories are interesting because they are no longer standing alone. A small but growing body of research is beginning to connect GLP-1 receptor signaling with migraine burden, brain inflammation, trigeminal pain pathways, intracranial pressure, and metabolic health.
Explore GLP-1 care with medical guidance
Nutree Clinic supports eligible patients with clinician-guided metabolic care that looks beyond the scale — including appetite, tolerance, nutrition, whole-body wellness, and realistic goals.
Headache as a side effect is not the same as migraine improvement
Before looking at the research, it is important to separate two different questions.
The first is: Can GLP-1 medications cause headache as a side effect? Yes. Some patients report headaches while taking GLP-1 medications. This may relate to reduced food intake, dehydration, nausea, lower caffeine intake, dose escalation, or individual sensitivity.
The second question is different: Can GLP-1 medications reduce migraine frequency or migraine burden in some patients?
That is the question patients are asking when they say, “My migraines improved after starting a GLP-1.” Large obesity and cardiometabolic trials may report headache as an adverse event, but they usually do not measure migraine as a treatment outcome. They do not typically track migraine days, aura, triptan use, disability, or whether chronic migraine becomes episodic.
So to understand a possible migraine benefit, we need migraine-focused studies, medication-use data, and mechanistic research — not only general adverse-event tables.
The first direct migraine signal: liraglutide
The strongest direct human signal so far comes from a 2025 prospective pilot study of liraglutide in patients with obesity and high-frequency or chronic migraine.
The study included 31 patients with obesity and difficult-to-treat migraine. Participants received liraglutide as an add-on treatment for 12 weeks. Average monthly headache days decreased from 19.8 days to 10.7 days.
That is a meaningful change. Even more interesting, body mass index changed only slightly during the study, and BMI reduction did not predict headache improvement. The authors suggested that the effect may not have been driven only by weight loss.
But the limits matter. The study was small, open-label, uncontrolled, and short. There was no placebo group. It cannot prove liraglutide prevents migraine. Still, it gives researchers a direct clinical signal to investigate in larger trials.
The semaglutide clue: fewer triptan prescriptions
Another important clue comes from a large Danish registry study evaluating semaglutide and triptan use.
Triptans are prescription medications used to treat acute migraine attacks. They are not usually taken every day to prevent migraines. They are taken when a migraine begins or when a patient feels one coming.
That makes triptan use an imperfect but useful proxy. If a large group of people starts using fewer triptans after beginning a medication, it may suggest fewer or less severe migraine attacks — although it does not prove that directly.
The Danish study included 189,392 adults who started semaglutide for weight management. After semaglutide initiation, triptan use gradually decreased. The reduction was modest overall, but stronger among people who were already using triptans before starting semaglutide.
This was not a migraine diary study. It did not directly measure monthly migraine days, migraine severity, aura, triggers, or actual weight-loss response. But as a real-world signal, it matters: among people starting semaglutide, especially those with a history of migraine treatment, acute migraine medication use may decrease over time.
Tirzepatide: an early case signal, not proof
The migraine-specific evidence for tirzepatide is even earlier.
A 2026 case series reported two patients with migraine who experienced reduced migraine headache frequency after starting tirzepatide, a dual GIP and GLP-1 receptor agonist.
This is interesting, but it must be interpreted carefully. The case series included only two patients total. Both patients also lost weight, which makes it impossible to know whether the improvement was related to tirzepatide itself, weight loss, improved metabolic health, reduced inflammation, better sleep, or a combination of factors.
So the tirzepatide case series should not be treated as proof. It is better understood as an early clinical observation — one more reason to study the question seriously.
The brain pathway: CGRP, microglia, and central sensitization
The most compelling part of this story is not only the human data. It is the biology.
Migraine is not just a “bad headache.” It involves complex signaling between the brain, trigeminal nerve pathways, blood vessels, inflammatory mediators, and pain-processing regions. One of the most important migraine pathways is CGRP, or calcitonin gene-related peptide. CGRP-targeting medications are now widely used as migraine-specific therapies.
Animal studies suggest that GLP-1 receptor activation may influence some of these migraine pathways. In a chronic migraine mouse model, researchers found GLP-1 receptors in the trigeminal nucleus caudalis, a key pain-processing region involved in migraine. Liraglutide reduced migraine-like pain behavior and affected markers linked to central sensitization, including CGRP and c-fos. It also reduced microglial activation and lowered inflammatory cytokines such as IL-1β and TNF-α.
Another study suggested that liraglutide may reduce migraine-like pain through IL-10, an anti-inflammatory cytokine.
Animal migraine models are not the same as human migraine disease. But they make the patient observations more biologically plausible.
The pressure pathway: GLP-1s and intracranial pressure
There is another possible explanation that may apply to a subset of patients: intracranial pressure.
Idiopathic intracranial hypertension, or IIH, is a condition in which pressure around the brain is elevated. It can cause chronic headache, visual symptoms, and migraine-like headache patterns. IIH is more common in women with obesity.
This matters because GLP-1 receptor agonists are being studied in IIH. Research suggests that GLP-1 receptors in the choroid plexus may influence cerebrospinal fluid production and intracranial pressure.
In a randomized clinical trial, exenatide reduced intracranial pressure in patients with active IIH. Headache outcomes also moved in a favorable direction, although the study was not a migraine-prevention trial.
This does not prove that GLP-1s treat migraine. But it raises an important possibility: some patients with chronic migraine-like headaches may have an overlapping pressure-related component, especially when obesity, chronic daily headache, visual symptoms, or IIH-like features are present.
The metabolic pathway: obesity, inflammation, and insulin resistance
There is also a broader metabolic explanation.
Obesity is associated with migraine frequency and migraine chronification. The relationship may involve inflammatory signaling, adipose tissue dysfunction, insulin resistance, sleep disruption, hormonal changes, and appetite-regulating pathways.
GLP-1 medications may improve several of those factors at once. They can reduce weight, appetite dysregulation, visceral fat, insulin resistance, and chronic low-grade metabolic inflammation in selected patients. Any of these changes could plausibly reduce migraine burden in some individuals, especially when migraine is worsened by obesity, inflammation, poor sleep, or metabolic stress.
This may be why the relationship is difficult to study. A patient may improve because of weight loss, lower inflammation, better sleep, reduced intracranial pressure, changes in trigeminal signaling, or several of these mechanisms together.
What we can and cannot say today
The research does not prove that GLP-1 medications are migraine treatments. But it does suggest that the patient stories are worth taking seriously.
A small liraglutide pilot study showed fewer monthly headache days in patients with obesity and high-frequency or chronic migraine. A large semaglutide registry study found reduced triptan use after treatment initiation. A tirzepatide case series reported improvement in two migraine patients. Animal studies suggest GLP-1 receptor activation may influence CGRP, microglia, neuroinflammation, and central sensitization. IIH research suggests GLP-1 receptor agonists may affect intracranial pressure and headache burden in pressure-related headache disorders.
This is not enough to promise migraine relief. But it is enough to ask a better question: in which patients might GLP-1 therapy reduce migraine burden — and through which pathway?
The Nutree Clinic perspective
At Nutree Clinic, we do not present GLP-1 medications as migraine treatments. Migraine is a neurological condition that deserves proper medical evaluation, especially when headaches are new, severe, changing, associated with vision symptoms, or different from a patient’s usual pattern.
But we also believe patient observations matter. When patients report fewer migraines after starting GLP-1 care, that experience should not be dismissed. It should be understood carefully, tracked thoughtfully, and placed in the context of emerging research.
The most responsible message is also the most interesting one: GLP-1 medications may be teaching us that weight, appetite, inflammation, intracranial pressure, and brain pain pathways are more connected than we once thought.
Frequently asked questions
Can GLP-1 medications help migraines?
Possibly for some patients, but this is not proven. Early research suggests GLP-1 receptor agonists may reduce migraine burden in certain groups, especially patients with obesity or metabolic factors, but larger randomized migraine-specific trials are needed.
Are semaglutide or tirzepatide approved for migraine?
No. Semaglutide and tirzepatide are not approved as migraine treatments. Migraine should be evaluated and managed with appropriate neurological or medical care.
Why would GLP-1s affect migraine at all?
Possible explanations include effects on metabolic inflammation, insulin resistance, weight, intracranial pressure, CGRP-related pathways, microglial activation, neuroinflammation, and central sensitization. These mechanisms are still being studied.
Can GLP-1 medications cause headaches?
Yes, some patients report headache as a side effect. This may relate to reduced intake, dehydration, nausea, dose changes, or individual sensitivity. Headache as a side effect is different from migraine improvement as a treatment outcome.
What is a triptan?
A triptan is a prescription medication used to treat an acute migraine attack after it starts. Examples include sumatriptan, rizatriptan, zolmitriptan, and eletriptan. In research, reduced triptan use may suggest reduced migraine burden, but it is still an indirect measure.
Should someone take a GLP-1 only for migraine?
No. GLP-1 medications should not be used as migraine treatments. They should only be prescribed when clinically appropriate based on medical history, eligibility, risks, and treatment goals. Migraine care should be managed separately with appropriate medical guidance.
Curious whether GLP-1 care is right for you?
Nutree Clinic offers clinician-guided GLP-1 care with personalized review, careful dosing, and follow-up that adapts to your body.
You may also like
References
- Braca S, Russo CV, Stornaiuolo A, et al. Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study. Headache. 2025;65(10):1831-1838. doi:10.1111/head.14991. Full text
- Roland CB, et al. Impact of semaglutide introduction on the use of triptans: an interrupted-time series. The Journal of Headache and Pain. 2026;27:199. doi:10.1186/s10194-026-02462-4. Full text
- Shah N, et al. Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series. Headache. 2026. doi:10.1111/head.70152. Full text
- Halloum W, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. The Journal of Headache and Pain. 2024;25:112. doi:10.1186/s10194-024-01821-3. Full text
- Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation. The Journal of Headache and Pain. 2021. PubMed
- GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model. Neuroscience Letters. 2023. PubMed
- Gultekin M, et al. Assessment of serum glucagon-like peptide-1 and dipeptidyl peptidase-4 levels in patients with migraine. Acta Neurologica Belgica. 2025. PubMed
- Mitchell JL, et al. The effect of GLP-1 receptor agonist exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821-1830. Full text
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526. doi:10.1056/NEJMoa2301972. Full text
- U.S. Food and Drug Administration. WEGOVY (semaglutide) prescribing information. Prescribing information
- U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) prescribing information. Prescribing information
Medical disclaimer: This content is for educational purposes only and does not provide medical advice, diagnosis, or treatment. GLP-1 medications are prescription medications and are not approved treatments for migraine. Migraine, severe headache, new headache patterns, visual symptoms, neurological symptoms, or worsening headaches should be evaluated by a qualified medical professional. Nutree Clinic does not treat migraine, neurological disease, idiopathic intracranial hypertension, or medical emergencies. Eligibility for GLP-1 treatment requires clinical evaluation by a licensed clinician. Results vary, and no outcome is guaranteed.